Latest Gustav Gaudernack Stories
TUBINGEN, Germany, March 27, 2013 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive(®) cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer. The Phase 2b trial will enroll up to 200 patients in eight European...
UT MD Anderson scientists find common vaccine ingredient diverts T cells from tumors Cancer vaccines that attempt to stimulate an immune system assault fail because the killer T cells aimed at tumors instead find the vaccination site a more inviting target, scientists at The University of Texas MD Anderson Cancer Center report in Nature Medicine. A common substance used in many cancer vaccines to boost immune attack betrays the cause by facilitating a buildup of T cells at the...
OSLO, January 31, 2013 /PRNewswire/ -- 18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013. Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer...
TUEBINGEN, Germany, November 8, 2012 /PRNewswire/ -- immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10...
FREDERICK, Md., Aug. 27, 2012 /PRNewswire/ -- Vaccinogen, Inc. today announced Dr. Michael G. Hanna, Jr., Vaccinogen CEO and co-founder, has served as guest-editor and contributor for the Human Vaccines & Immunotherapeutics Special Focus on cancer vaccines and immunotherapeutics, one of the most comprehensive peer-reviewed discussions published on the field. The Special Focus highlights nearly two decades of research and clinical development programs and, for the first time,...
